Photo of Aaron Miller

Aaron Miller

  • PROFESSOR Neurology
Print ProfilePrint Profile

Specialty

Certifications

  • Neurology, American Board of Psychiatry and Neurology

  • American Board of Internal Medicine

Clinical Focus

Education

  • MD, New York University

  • Residency, Internal Medicine
    Jacobi Hospital Center

  • Residency, Neurology
    Bronx Municipal Hospital Center

  • Residency, Neurology
    Bronx Municipal Hospital Center

Biography

    Aaron Miller, M.D. is widely recognized as a preeminent MS clinician and has been recruited to direct clinical affairs at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis. In addition, he is Co-Director of the Multiple Sclerosis Care Center at Maimonides Medical Center in Brooklyn.

    Dr. Miller is a member of the Board of Directors of the American Academy of Neurology, and serves as Editor of Continuum, the AAN's bi-monthly continuing education publication. He is active in the New York City chapter of the National Multiple Sclerosis Society, where he serves as Chairman of the Clinical Advisory Committee.

    He is a past president of the Consortium of MS Centers, and was the first chairman of the Multiple Sclerosis section of the American Academy of Neurology. He has participated in numerous MS clinical trials, and is the principal investigator for several ongoing trials of new treatments at the CGD Center.

Awards

  • 2011 -
    Best Doctors
    New York Magazine

  • 1985 - current
    Fellow
    American Academy of Neurology

  • 1979 - 1981
    Teacher-Investigator Award
    NINCDS

  • 1968 -
    Alpha omega alpha
    New York University School of Medicine

  • 1964 -
    Phi beta kappa
    Mu chapter of Massachusetts, Brandeis University

Research

Database and Registry

New York State Consortium of Multiple Sclerosis Centers (establishing MS registry and database to be used for multiple collaborative projects)

Publications

Miller A, Bourdette D, Cohen JA, Coyle PK, Lublin F, Paty DW, Rice GP, Weinstock-Guttman B, editors. Multiple Sclerosis. New York, Continuum; 1999.prettyprintp1-196.

Miller A. Paroxysmal Disorders. In: Burks JS, Johnson KP, editors. Multiple Sclerosis. Diagnosis, Medical Management and Rehabilitation. New York, Demos Medical Publishing, Inc.; 2000.

Miller A, Herndon RM. Treatment Issues. In: Kalb RC, editor. Multiple Sclerosis. The questions you have-the answers you need. Second New York, Demos Medical Publishing, Inc.; 2000.

Miller A. Clinical Features. In: Cook SD, editor. Handbook of Multiple Sclerosis. Third New York, Marcel Dekker, Inc.; 2001.

Sand IK, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 2014 Feb;.

Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Neurology 2014 Oct; 13(10).

Miller AE, Macdonell R, Comi G, Freedman MS, Kappos L, Mäurer M, Olsson TP, Wolinsky JS, Bozzi S, Dive-Pouletty C, O'Connor PW. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of neurology 2014 Sep; 261(9).

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014 Jul; 83(3).

Sand IK, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 2014 Feb;.

Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple sclerosis (Houndmills, Basingstoke, England) 2014 May; 20(6).

Miller AE, Cohen BA, Krieger SC, Markowitz CE, Mattson DH, Tselentis HN. Constructing an adaptive care model for the management of disease-related symptoms throughout the course of multiple sclerosis--performance improvement CME. Multiple sclerosis (Houndmills, Basingstoke, England) 2014 Jan; 20(1).

.;.

O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson TP, Miller AE, Dive-Pouletty C, Bégo-Le-Bagousse G, Kappos L. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. Journal of neurology 2013 Oct; 260(10).

Rudick RA, Miller AE. Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis. Neurology 2012 Jun; 78(24).

Miller AE, Rhoades RW. Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs. Current opinion in neurology 2012 Feb; 25 Suppl.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Miller during 2013 and/or 2014. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting:

  • Acorda Therapeutics Inc.; Biogen Idec; CVS Caremark; Campbell Alliance Group, Inc.; Gerson Lehrman Group; Novartis; Nuron Biotech Inc.

Scientific Advisory Board:

  • Questcor Pharmaceuticals, Inc.; sanofi-aventis

Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.

  • Pharmaceutical Product Development, Inc. (PPD)

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

5 East 98th Street, 1st Floor
New York, NY 10029

Tel: 212-241-6854
Fax: 212-241-5333
Get Directions

Office Hours:
  • Monday 9:00am - 5:00pm
  • Tuesday 9:00am - 5:00pm
  • Wednesday 9:00am - 5:00pm
  • Thursday 9:00am - 5:00pm
  • Friday 9:00am - 5:00pm